Eph receptors and their ephrin ligands were identified in the late 1980's. Subsequently, they were linked to different physiological and pathophysiological processes like embryonic development, angiogenesis, and tumorigenesis. In this regard, recent work focused on the distribution and effects of Eph receptors and ephrins on tumor cells and tumor microenvironment. The purpose of this review is to outline the role of these molecules in physiological angiogenesis and pathophysiological tumor angiogenesis. Furthermore, novel therapeutical approaches are discussed as Eph receptors and ephrins represent attractive targets for antiangiogenic therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2836134 | PMC |
| http://dx.doi.org/10.1155/2010/135285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum EphA2 as a Promising Biomarker for the Early Detection and Diagnosis of Colorectal Cancer.
Biomolecules
November 2024
Institute of Life Innovation Studies, Toyo University, Tokyo 115-8650, Japan.
Background: EphA2, a receptor-type tyrosine kinase, is overexpressed in several cancers, including colorectal cancer (CRC), and can be detected as soluble EphA2 in serum. This study aimed to investigate the relationship between soluble EphA2 and CRC.
Methods: Serum samples were collected from 65 patients with CRC and 19 healthy individuals.
Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.
Clin Transl Med
January 2025
Frazer Institute, Faculty of Medicine, The University of Queensland, Woolloongabba, Queensland, Australia.
Background: Paediatric sarcomas, including rhabdomyosarcoma, Ewing sarcoma and osteosarcoma, represent a group of malignancies that significantly contribute to cancer-related morbidity and mortality in children and young adults. These cancers share common challenges, including high rates of metastasis, recurrence or treatment resistance, leading to a 5-year survival rate of approximately 20% for patients with advanced disease stages. Despite the critical need, therapeutic advancements have been limited over the past three decades.
View Article and Find Full Text PDFInhibition of EphA2 by syndecan-4 in wounded skin regulates clustering of fibroblasts.
J Mol Cell Biol
December 2024
School of Biochemistry, University of Bristol, University Walk, Bristol BS8 1TD, United Kingdom.
Upon injury, fibroblasts in the surrounding tissue become activated, migrating into the wound in a controlled manner. Once they arrive, they contract the wound and remodel the stroma. While certain cell surface receptors promote fibroblast migration, others cause repulsion between fibroblasts upon contact, seemingly opposing their clustering within the wound bed.
View Article and Find Full Text PDFEFNA4-enhanced deubiquitination of SLC7A11 inhibits ferroptosis in hepatocellular carcinoma.
Apoptosis
December 2024
Southern Medical University Hospital of Integrated Traditional Chinese and Western Medicine, Southern Medical University, Guangzhou, 510315, China.
Article Synopsis
- EFNA4 influences liver cancer (HCC) through two mechanisms: one that binds to Eph receptors and another that operates independently of them.
- Despite a lack of Eph receptors, EFNA4 still promotes HCC cell growth and spread as well as inhibiting ferroptosis, a type of cell death.
- The study reveals that EFNA4 interacts with the protein SLC7A11 to prevent its degradation, enhancing HCC progression and suggesting EFNA4 as a potential marker and target for HCC treatment.
Constrained β-Hairpins Targeting the EphA4 Ligand Binding Domain.
J Med Chem
December 2024
Division of Biomedical Sciences, School of Medicine, University of California Riverside, 900 University Avenue, Riverside, California 92521, United States.
The activity of the receptor tyrosine kinase EphA4 has been implicated in several pathologies including oncology (gastric and pancreatic cancers) and neurodegenerative diseases (amyotrophic lateral sclerosis and Alzheimer's disease). However, advances in validating EphA4 as a possible drug target have been limited by the lack of suitable pharmacological inhibitors. Recently, we reported on the design of potent EphA4 agonistic agents targeting its ligand binding domain (LBD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!